Stage C EAL+ patients had median PFS of 15 mons, Stage C EAL- patients – 21 mons (p=0,05) Stage B EAL+ patients had median PFS of 20 mons, Stage B EAL- patients – 58 mons (p=0,004) Thus, unmutated patients wit EAL had similar PFS with mutated patients without EAL. VH-mut- EAL+ patients had median PFS of 11 mons, VH-mut- EAL- patients – 18 mons (p=0,06) VH-mut+ EAL+ patients had median PFS of 18 mons, VH-mut+ EAL- patients – 58 mons (p=0,06) Thus, CD38+ patients without EAL had even better PFS than CD38- patients with EAL. The differences of PFS were also studied inside the groups defined by standard prognostic markers.ĬD38-, EAL+ patients had median PFS of 23mons, CD38-, EAL- patients-median not achieved (p= 0.01)ĬD 38+EAL+patients had median PFS of 12 mons, CD38+EAL- patients – 30 mons (p=0,04) The duration of CR and PR were longer in patients without EAL(resp.p = 0.03 and 0.06, Fig. Difference in PFS has been also revealed in FC and FCR subgroups: 16 and 25 mons, p=0,003 for FC 22 and 56 mons, p=0,01 for FCR (Fig.1)Īll fludarabine containing regimens resistant patients appeared to have EAL (10 pts). PFS was lower in the group of patients with EAL in comparison to patients without EAL(18 and 48 mons, p 0.001). CD38 positivity, unmutated type and stage C had adverse prognostic significance in the whole group (p= 0,04 p=0,05 p=0,02), in FCR subgroups, mutation status and CD38 had marginal significance in FCR(p=0.9, p=0.75).Ībdominal lymph nodes were enlarged in 41 pts (58%), 16 pts had bulky EAL(23%).
FCR: OR 91%, CR 67%, PR 24%), median of PFS was 26 mons (21 mons for FC and 35 for FCR, p=0.006). In the whole group, FC: OR 81%, CR 46%, PR 35%. Overall response (OR) was 86% (61 pts), the rate of CR was 55% (39 pts), the rate of PR 31% (22 pts).
0 kommentar(er)
